CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 106 enrolled
Drug / intervention
SRX246 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02507284
NCT02507284Phase 2Completed
CompareCT.gov

An Exploratory Phase II Study to Determine the Tolerability, Safety, and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Irritable Subjects With Huntington's Disease (HD)

Azevan Pharmaceuticals·interventional·Posted Jul 23, 2015·Updated Jul 20, 2023

In Brief

A Phase 2 clinical trial evaluating SRX246 and Placebo for Irritable Mood and Huntington's Disease. Completed, enrolled 106 participants across 22 sites.

Detailed Summary

This study evaluates the tolerability, safety and activity of SRX246 in the treatment of irritability in patients with Huntington's disease. Two-thirds of all participants will receive SRX246, while the other third will receive a placebo.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIrritable Mood, Huntington's Disease
CountriesUnited States
CollaboratorsNational Institute of Neurological Disorders and Stroke (NINDS), NeuroNEXT Network

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedJul 23, 2015
Enrollment StartMay 10, 2016
Primary CompletionSep 10, 2018
Study CompletionDec 21, 2018
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 10.9 years ago

Interventions

SRX246drug

Placebodrug